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Various factors make cord blood (CB) a significant source of hematopoietic stem cells 
(HSCs), including ease of procurement and lack of donor attrition, with the ability to 
process and store the donor cells long term. Importantly, high proliferative potential 
of the immature HSCs allows one log less use of cells compared to bone marrow or 
peripheral blood stem cells. As total nucleated cell (TNC) and CD34+ cell content of 
CB grafts are correlated to engraftment rate and speed, strategies to expand HSC 
and homing have been developed. This chapter will focus only on modalities such as 
intrabone administration, fucosylation, CD26 inhibition, prostaglandin E2 derivative or 
complement 3 exposure, and SDF-1/CXCR4/CXCL-12 pathway interventions that have 
been experimented successfully. Furthermore, increasing evidence in line with better 
recognition of CB progenitors that are involved in engraftment and homing will also be 
addressed.
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The first decade of unrelated donor CBT (UCBT) experience was important in defining critical total 
nucleated cell (TNC) and CD34+ cell dose thresholds required for acceptable clinical outcomes, 
and in moving from related to UCBT and from pediatric to adult patients. The limitations of this 
approach also were defined during this period, with low cell dose identified as the critical barrier. 
Using double CB units (dUCBT) was a solution attempted by a group in Minnesota in 2000. Since 
then, the method has been proven to be safe and feasible. The advent of dUCBT brought a significant 
reduction in the risk of graft failure, opening up the possibility of HSCT with CB for essentially all 
patients without a suitable donor. Nonetheless, the use of dUCBT did not produce faster neutrophil 
recovery or immune reconstitution. Due to the high cost, it was limited to adult patients to reach 
the lower threshold. Thus, the advent of dUCBT has led to increased activity in the area of CB 
graft engineering, especially in the field of ex vivo expansion. Intrinsic and extrinsic cellular factors 
have been proven to act roles in hematopoietic stem cell (HSC) expansion, thus justifying their 
role in in vitro and ex vivo culture conditions. Attempts to regulate these factors through ex vivo 
expansion methods aim to overcome insufficient cell numbers. Delaney et al. achieved significant 
success justifying the role of triggering Notch-mediated signaling by Notch ligands (1, 2). Enhanced 
generation of CB hematopoietic stem and progenitor cells by culture with StemRegenin1 and Delta1 
(Ext-IgG) was another ex vivo expansion approach from the same group (3). StemRegenin (HSC835) 
approach has later been undertaken by the Minnesota group and two Phase I/II clinical trials are 
ongoing (Clinical Trial Identifier: NCT01930162 and NCT01474681, respectively). In addition, 
Phase I/II clinical trials to evaluate the impact of infusion of expanded cryopreserved cord blood 
(CB) progenitor cells with Notch ligand or nicotinamide (NiCord) (Clinical Trial Identifier: NCT 
01175785 and NCT01816230, respectively) on augmenting the UCBT outcome are ongoing in Fred 
Hutchinson and Duke Universities.
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Apart from the expansion protocols applied for increas-
ing cell dose, several other promising notions have also been 
introduced: optimal selection of HLA matching CB units, killer 
immunoglobulin-like receptor (KIR) typing of the candidate 
units; modification of conditioning as well as GVHD prophylaxis 
regimens; post-transplant use of growth factors/cytokines; and 
infusion of the CB with accessory mesenchymal stem cells (MSC) 
are of the most forthcoming modalities as nicely detailed in the 
recent review by Rocha et  al. (4). Results of a clinical trial led 
by MD Anderson Cancer Center (Clinical Trial Identifier: NCT 
00498316) for testing CB expansion on MSC has been addressed 
in this issue of the journal (5). Despite the fact that many differ-
ent strategies have gained attention with various fold increases in 
CD34+ cell numbers, delayed immune reconstitution remains a 
major challenge after UCBT. There are currently many ongoing 
in  vitro/in  vivo experiments along with preclinical and clinical 
trials for the evaluation of different strategies for improving 
engraftment after UCBT (6–9). This review aims to summarize 
the most prominent approaches those having impact on HSC 
engraftment with the exception of double UCBTs as this approach 
has become an established transplant modality for patients who 
lack an HLA matched adult donor.
PReDiCTORS OF enGRAFTMenT
Generally, TNC and CD34+ are considered to be the best predic-
tors of engraftment standard for selection of units. As discussed in 
detail in the review by Beksac and Preffer, quantification of HPSC 
capacity of a graft is still not standardized and differs according to 
the source of stem cells (10). In the CB, TNC contains a consider-
able number of normoblasts and lymphocytes. The marrow TNC 
is more heterogeneous. In CB, the CD34+ per microliter is almost 
as high as the counts following 3–4 days of G-CSF administration. 
Migliaccio et al. (11) have compared TNC with colony-forming 
unit (CFU) numbers and have shown TNC to be inferior to CFU 
in determining neutrophil and platelet recovery speed following 
UCBT. Recently, Simmons et  al. have identified a CD34+ cell 
subpopulation that co-expresses an antigen (-MA6) (12). This 
antigen expression predicted platelet engraftment better than 
CD34+ cell counts. In this study comparison of PBSC with CB, it 
revealed less frequent MA6 expressing cells within CB (<0.2%) 
than PBSC (8%) CD34+ cells. This finding provides an explana-
tion to slower platelet recovery following single UCBTs. The 
impact of megakaryocytic lineage commitment within CD34+ 
cells following in vitro manipulation of CB is not known yet.
inTRABOne inFUSiOn
Historically, the earliest HSCT experience was performed using 
bone marrow (BM) with direct intrabone infusion. As this 
approach required technical expertise and induced pain in the 
recipient, it was later replaced by central venous administration 
through catheters. Frassoni et al. were the pioneers to revisit intra-
bone application in UCBT (13). Their preliminary results on 44 
patients were able to show neutrophil and platelet recovery times 
to be 23 and 36 days, respectively. Full donor type chimerism was 
obtained among all patients. This success tempted investigators 
to perform a retrospective registry-based analysis, to compare 
outcomes of results from intrabone single IB-UCBT (n:87) vs. 
dUCBT (n:149) after myeloablative conditioning regimen (4). 
Although the median number of TNC were lower among the 
IB-UCBT (2.5  ×  10 vs. 3.9  ×  10/kg, P  <  0.001), neutrophil 
recovery (76 vs. 62%, P =  0.014), median time to engraftment 
(23 and 28 days, P = 0.001), and platelet recovery (74 vs. 64%, 
P =  0.003) were better. In multivariate analysis, IB-UCBT was 
associated with higher neutrophil and platelet recovery and lower 
acute graft-versus-host disease (II-IV) (P < 0.01). IB-UCBT did 
not increase TRM and there was a trend for longer PFS.
enHAnCinG BOne MARROw HOMinG
Full recovery of tri-lineage hematopoiesis following stem cell 
transplantation depends on proper engraftment of transplanted 
cells, which relies on engraftment of the most primitive long-term 
repopulating HSCs (1) To overcome the negating effects of low 
counts of HSC within CBUs, strategies to improve homing of HSCs 
to the marrow have been developed. Recently, two new strategies 
have been proposed. The first is based on inhibition of human 
analog of the murine-identified HSC-expressed dipeptidyl-
peptidase (CD26). The second, developed by Minnesota group, 
is based on ex vivo priming of HSCs before transplantation with 
small molecules, such as C3 complement fragments, fibrinogen, 
fibronectin, and hyaluronic acid. This second strategy has been 
adopted by other groups, such as the investigators in Brigham’s 
Hospital, who have used a prostaglandin E2 derivative to facilitate 
homing and induce hematopoietic progenitor proliferation (14).
effects of CD26 and Modification of 
CXCR4-SDF-1 Axis
SDF-1, a BM stromal cytokine, plays a significant role in homing 
of HSCs in BM niche through binding its receptor CXCR-4. It 
has been suggested that retention of CB cells in the BM depends 
highly on the level and SDF-1 binding capacity of CXCR4 after 
transplantation and allogeneic engraftment (15). Moreover, an 
efficient SDF-1 gradient and adequate responsiveness of CXCR-4 
receptors to SDF-1 in the BM microenvironment are proven to 
be one of the main cellular events providing engraftment of HSCs 
in BM (16, 17). Through interaction between cells expressing 
CXCR4 and inflammatory chemotactic molecules, matrix metal-
loproteinases (MMPs), and angiopoietic factors (e.g., VEGF) 
SDF-1/CXCR4 axis plays a crucial role by increasing seeding 
efficiency and speed (1, 17).
The Indianapolis team led by Broxmeyer was the first to dis-
cover inhibition or deletion of CD26 on donor cells to enhance 
short-term homing, long-term engraftment, competitive 
repopulation, secondary transplantation, and mouse survival 
in an experimental model. Their pivotal findings suggest that 
CD26 is a novel target for increasing transplantation efficiency. 
The peptidase CD26 [DPPIV (dipeptidylpeptidase IV)] removes 
dipeptides from the amino terminus of proteins. They provided 
evidence that endogenous CD26 expression on donor cells 
negatively regulated homing and engraftment. CD26 is a widely 
expressed membrane-bound ectopeptidase that cleaves CXCL12, 
thereby depleting its chemokine activity and explains the 
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homing/engraftment effects. Based on this fact, inhibition of the 
enzyme (CD26/DPPIV) cleaving SDF-1/CXCL-12 (CXCR4) into 
a truncated form has been a promising approach to retain the 
hindered chemotactic effect.
Many different researchers have also provided in  vitro and 
in  vivo data that inhibition of CD26/DPPIV clearly enhanced 
colony stimulating activity as well as engraftment capacity of 
CB HSCs (17, 18). The clinical efficacy of a DPP-IV inhibitor 
(Sitagliptin), FDA approved for treatment of type II diabetes 
mellitus, is under investigation in two clinical Phase II stud-
ies. Led by Sherif Farag, authors observed a speed up and 
enhancement of engraftment following CB transplantation 
(Clinical Trial Identifiers: NCT 00862719 and NCT 01720264) 
(19). Among 24 patients following a MAC regimen and oral 
600 mg Sitagliptin (−1 to +2 days) suppressed DPP4 activity by 
~70–80%, although the effect was not permanent with a return 
to baseline activity levels within 16 h of administration. A key 
finding was a significant correlation between level of DPP4 
suppression and neutrophil engraftment (P = 0.002). However, 
the optimal Sitagliptin dose as well as the duration needs to be 
further investigated clinically (9, 19).
SDF-1 regulates the trafficking of pre-B lymphocytes and T 
lymphocytes in addition to CD34+ HSCs. Thus, modulation of 
cell trafficking by SDF-1, particularly via adhesion molecules, also 
happens to effect survival of CB T cells in BM environment. These 
data justifies CXCR4-SDF-1 axis’ role in homing and mediating of 
allogeneic CB engraftment of cells that need to combat recipient 
immune-mediated graft rejection (15).
Recently, the Leuven group led by C. Verfaille identified a 
new inhibitor: tissue factor pathway inhibitor (TFPI) that acts 
as a biological CD26 inhibitor on human marrow or CB hemat-
opoietic progenitor and stem cells. TFPI exerts activity through 
Glypican-3, which is co-expressed with CD26. Their experimen-
tal results have not entered clinical trials yet.
These results suggest that HSC engraftment is not absolute, 
as previously thought, and indicate that improvement of BM 
transplant efficiency may be made possible in the clinic.
C3a–C3aR Axis
One of the major components of the innate immune system is 
the complement cascade proteins. Treatment with complement 
proteins, C3a in particular, has been shown to enhance ex vivo 
transmigration of CD34+ HSCs from CB and BM via elevating 
the expression of CXCR-4 and MMP-2/MMP-9. Short-term 
priming of CB-derived CD34+ HSCs may upregulate levels of 
homing-related molecules. Their ex vivo trans-migratory and 
in vivo homing potential may overcome the delayed reconstitu-
tion after UCB (1).
Ratajczak and co-workers showed that the complement cas-
cade is activated during growth-factor-induced hematopoietic 
progenitor and HSCs mobilization and that complement cleavage 
fragments play a part in the mobilization. It was reported that the 
C3a receptor (C3aR) is expressed on CB CD34+ cells and that 
CD34+-cell migration toward SDF-1 could be enhanced through 
C3a in vitro (20). In addition, after pretreatment of CB CD34+ 
cells with a C3aR antagonist (SB290157) homing after transplan-
tation into NOD/SCID mice was impaired (21, 22). In the Phase 
I clinical trial led by Brunstein et al., the effect of C3a priming 
was investigated following one primed and one unmanipulated 
CB among patients with high-risk hematological malignancies 
(23). In this double CB platform, median time to engraftment 
was 6 days, which was not significantly different from the time 
to engraftment of historical non-myeloablative UCBT control 
patients. Engraftment was dominated by the C3a-primed CBU 
among nine of 27 evaluable patients. Engraftment was driven by 
the CD3+-cell content of the CBU. CD3+ more than 0.5 × 107 cells/
kg determined the winner (23).
Modulation with Prostaglandin e2
The stable prostaglandin E2 derivative 16,16-dimethyl prosta-
glandin E2 (dmPGE2) has been identified as a critical regulator 
of HSC homeostasis following screening among many chemical 
molecules in a zebra fish embryo model (24). A brief incubation 
with dmPGE2 up-regulates the genes responsible from homing 
(e.g., CXCR4), proliferation (e.g., CyclinD1), and cell survival 
(e.g., Survivin) (14). Authors hypothesized that brief ex vivo 
modulation with dmPGE2 could improve patient outcomes by 
increasing the “effective dose” of HSCs. In a Phase I trial fol-
lowing a RIC dUCBT, they were able to achieve accelerated and 
long-term neutrophil engraftment (17.5 vs. 21 days, P = 0.045). 
The dominating CBUs were those exposed to dmPGE2 in 10/12 
of CBTs. Furthermore, there were no adverse events or safety 
issues related to ex vivo dmPEG2 exposure. A Phase II clinical 
trial (NCT01627314) is underway to further investigate the 
feasibility and effectiveness of this manipulation. These authors 
have expanded their research to discover dmPEG2 priming to 
modify Wnt signaling resulting in T cell factor (TCF)-mediated 
transcription. Wnt signaling upregulated interleukin (IL)-7R and 
IL-2Rβ expression resulting in enhanced survival mediated by the 
homeostatic cytokines IL-7 and IL-15 (25). This novel approach 
induces and maintains naive, memory precursors, and long-lived 
central memory CD8+ cells. These immune-mediated effects are 
very promising as immune reconstitution is delayed following 
CBT and constitutes one of the major problems.
Fucosylation
Delayed engraftment was shown to be due, at least in part, to low 
fucosylation (the addition of a fucose molecule) of cell surface 
molecules important for homing to the BM microenvironment. 
Interaction among adhesion molecules within the BM micro-
niche depends on the fucosylation of CB HSC. A simple 30-min 
ex vivo incubation of CB hematopoietic progenitor cells with 
fucosyltransferase-VI and its substrate (guanosine diphosphate 
fucose) is sufficient to increase fucosylation (26, 27). Fucosylation 
has been shown to improve engraftment among irradiated NOD/
SCID mice (4). Moreover, Robinson et  al. demonstrated that 
only fucosylated CB CD34+ were responsible from engraftment 
among NOD-SCID interleukin-2Rγ (null) mice (28).
In MD Anderson Cancer Center, two Phase II clinical trials 
are underway to investigate the utility of CB CD34+ cell fuco-
sylation (Clinical Trial Identifiers: NCT 01471067 and NCT 
02423915, respectively). Expectations are to test clinical utility 
of fucosylated T cells with an aim to obtain faster engraftment 
and prevent GVHD among patients with leukemia–lymphoma. 
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Encouraging results supporting ex vivo fucosylation in dUCBT 
setting of the registered NCT 1471067 trial was recently pub-
lished by Popat et al. (27). Effects of fucosylation were evaluated 
among 22 patients enrolled in the trial. The median time to neu-
trophil engraftment was 17 days (range, 12–34 days) compared 
to 26  days (range, 11–48  days) observed in a control group of 
31 patients who had undergone double unmanipulated UCBT 
(P =  0.0023), Platelet engraftment was also improved: median 
was 35 days (range, 18–100 days) compared with 45 days (range, 
27–120 days) for controls.
CO-ADMiniSTRATiOn OF CB-DeRiveD 
PROGeniTOR OR nATURAL KiLLeR 
CeLLS
Another strategy to improve engraftment has been based on co-
administration of third party stem cells. Robin et al. have demon-
strated human stem and progenitor cells are detectable in placental 
tissue (29). Celgene Cellular Therapeutics (CCT) has developed 
a proprietary, sterile closed perfusion process for the collection 
of human placenta-derived stem cells (HPDSCs) from full term 
placentas. HPDSC are rich in HSCs and hematopoietic progeni-
tor cells, HSC and progenitor CFU forming capabilities, low in 
HLA Class I and II expression and enhance in vivo engraftment 
when combined with UCBT in NOD-SCID animals. Elmacken 
et al. have initiated a pilot study of adding universal donor (third 
party) HPDSCs with either single or double UCBT following 
myeloablative or reduced toxicity conditioning in children and 
adults with selected malignant and non-malignant diseases in 
a multicenter consortium (IND#14949; Clinical Trial Identifier 
NCT 01586455) (30). In their preliminary ASBMT 2015 abstract, 
they reported a median time to neutrophil engraftment of 22 days 
following a mean (±SD) cell dose of CD34+ (3.9 ± 1.8 × 105/kg) 
and HPDSC CD34+ (0.3 ± 0.15 × 105/kg) infusion.
The use of CB originated immune cells is one of the most 
promising immunotherapeutic strategies to be used after CBT (16, 
31–33). Induction or adoptive transfer of CB-derived immune 
cells, particularly natural killer (NK) cells and regulatory T cells 
(T reg) with or without cytokines are also effective approaches 
for gaining better engraftment levels after UCBT. All of these 
approaches have been denoted as “successful” in preclinical 
in vitro and animal studies (34–36).
The role of NK cells in engraftment is still controversial. 
Gertow et  al. have suggested that mixed chimerism following 
double UCBT could possibly be related to NK cell tolerance 
between the CB units; other reports, however, did not show a 
correlation between KIR ligand incompatibility and engraftment 
(37). Nonetheless, previous studies of HSC transplantation in 
mice demonstrated that IL-2-activated NK cells mediate HSC 
engraftment and that alloreactive NK cells may facilitate engraft-
ment by killing recipient T cells and APCs. As the reduced func-
tion and maturation of NK cells arising in the early post-UCBT 
period can be restored by cytokines, infusion of ex vivo expanded 
and activated NK cells could represent a means to enhance early 
engraftment following UCBT.
COnCLUSiOn
Until now, many expansion modalities with the ultimate goal of 
improving engraftment after UCBT were successful to a certain 
degree. It is of great interest that current evidence supports 
priming of CB cells prior to transplantation modulates/improves 
engraftment dynamics. In addition to generating increased num-
bers of progenitor cells with rapid in vivo re-population capacity, 
enhancing HSC homing capacities will improve the kinetics of 
hematopoietic recovery with better transplant outcome and 
hopefully less transplant related mortality rates.
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